Ilana Fogelman

Founded in 2003, LifeTech Research, Inc. is an investment research, technology development and due diligence firm located in Edgewater, Maryland. The firm provides due-diligence and business development services across the life sciences sector. They advise business development offices on product licensing and acquisition strategies and they support early-stage entrepreneurs with disruptive ideas and technologies. LifeTech also assists international financing agencies to facilitate the granting and lending of capital to improve economic welfare and societal health. LifeTech's research methods include (1) benchmarking (2) historic trend and meta-analysis (3) bias assessment and adjustment (4) decision analysis and Monte Carlo simulation (5) scenario analysis, back-testing and other statistical validation (6) advanced regression modeling and (7) risk and time-adjusted present value modeling.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

LifeTech Development Partners LP (LifeTech Development) is a venture capital subsidiary of LifeTech Research, Inc. founded in 2008 by Joel Braunstein. The firm is headquartered in Baltimore, Maryland.

Merrill Lynch, Pierce, Fenner & Smith, Inc. (MLPFS) is the SEC-registered broker/dealer subsidiary of Merrill Lynch & Co., Inc., ultimately held by Charlotte-based Bank of America Corp. (NYSE: BAC). The firm was founded in 1958 and is headquartered in New York City. In 2010, Banc of America Securities LLC merged with MLPFS and the firm uses the trade name Bank of America Merrill Lynch. MLPFS's global strategy and economics team serves institutional and individual investors using a wide range of macroeconomic disciplines. Their analysis of global issues provides clients with investment ideas, market forecasts, macro overviews and specific sector recommendations across asset classes, regions and disciplines. Their equity research team conducts fundamental analysis on companies globally and provides institutional and retail clients with industry-specific and in-depth research and analysis on numerous industries. The firm's global fixed-income and equity-linked research focuses on fixed-income and equity derivatives, fixed-income strategy, convertibles, commodities, high-yield, mortgages, municipals and global foreign exchange.

C2N Diagnostics LLC is a private company that focuses on mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company is based in St. Louis, MO. The company's lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including a?42, a?40, and apolipoprotein e isoforms. This test predicts brain amyloid plaques as determined by PET scan results and received a breakthrough device designation from the Food and Drug Administration in early 2019. C2N Diagnostics aims to bring accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring in the field of neurodegeneration and Alzheimer's disease. The company was founded by Ravi Kiron, Joel Bennett Braunstein, Ilana Fogelman. Joel Bennett Braunstein has been the CEO since incorporation.